PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

NCT ID: NCT00544674

Last Updated: 2012-12-10

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-08-31
• Study Completion Date: 2009-01-31

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well PR-104 works in treating patients with previously untreated or relapsed small cell lung cancer (SCLC).

Detailed Description

OBJECTIVES:

Primary

• Estimate the response rate of PR-104 in patients with treatment-naive or sensitive-relapse small cell lung cancer.
• Evaluate safety of this drug in these patients. Secondary
• Evaluate survival of these patients.
• Evaluate progression-free survival of these patients.
• Evaluate time to progression in these patients.
• Assess the pharmacokinetics (PK) of PR-104 and its alcohol metabolite.
• Estimate the rate of hypoxia using 18F-fluoromisonidazole (FMISO) positron emission topography (PET) imaging.
• Collect plasma samples for assessment of potential biomarkers of tumor hypoxia.

OUTLINE: This is a multicenter study. Patients are stratified according to disease type (treatment-naive vs sensitive-relapse).

Patients receive PR-104 intravenously (IV) over 1 hour on day 1. Treatment repeats every 21 days for up to 4 courses (for treatment-naive patients) or in the absence of disease progression or unacceptable toxicity (for sensitive-relapse patients).

PK studies are performed during course 1 and after course 3. Blood is collected at baseline, during course 1, and at study completion for biomarker studies of tumor hypoxia (plasma proteins). Patients also undergo FMISO PET and fludeoxyglucose F18 (FDG) PET scans at baseline and after the second course of study therapy.

Conditions

Lung Cancer

Keywords

extensive stage small cell lung cancer; limited stage small cell lung cancer; recurrent small cell lung cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

PR104

PR104 will be administered once every 21 days by IV

Group Type: EXPERIMENTAL

PR104

Intervention Type: DRUG

administered at a dose of 1100 mg/m\^2 by intravenous infusion over 1 hour and repeated every three weeks

F-18-fluoromisonidazole

Intervention Type: OTHER

administered intravenously prior to PET scan

Interventions

PR104

administered at a dose of 1100 mg/m\^2 by intravenous infusion over 1 hour and repeated every three weeks

Intervention Type: DRUG

F-18-fluoromisonidazole

administered intravenously prior to PET scan

Intervention Type: OTHER

Other Intervention Names

PR-104; FMISO

Eligibility Criteria

Inclusion Criteria

• Histologically or cytologically confirmed small cell lung cancer (SCLC)
• If patient is treatment-naive, then they must have extensive disease
• If patients are not treatment-naive, then they must be classified as sensitive-relapse with either extensive disease or limited disease

• Sensitive-relapse defined as disease that responded to first-line chemotherapy and relapsed more than 90 days following the last dose of first-line chemotherapy
• Limited disease SCLC defined as disease confined to the hemithorax of origin, mediastinum, and/or ipsilateral supraclavicular lymph nodes, which could be encompassed within a tolerable radiotherapy port
• Extensive disease defined as disease that does not fit the definition of limited disease as defined above
• Measurable or evaluable disease

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• Absolute neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Hemoglobin ≥ 9 g/dL (no red blood cell transfusions allowed)
• Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN (if liver metastases are present) or ≤ 2 x ULN (if liver metastases are absent)
• Serum creatinine ≤ 1.5 x ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for at least 30 days after completion of study treatment

• See Disease Characteristics
• No concurrent prophylactic growth factors (filgrastim [G-CSF] or sargramostim [GM-CSF]) during course 1 of study treatment

Exclusion Criteria

• Active central nervous system (CNS) metastases, defined as metastases to the CNS (symptomatic or non-symptomatic) that requires immediate treatment or that are likely to require treatment in the following 6 weeks
• Medical conditions requiring urgent intervention, including any of the following:

• Superior vena cava syndrome
• Lobar obstruction
• Spinal cord compression
• Liver metastases involving greater than one-third of the liver

PATIENT CHARACTERISTICS:

• Prior or concurrent malignancies, except for adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or localized low-grade prostate cancer
• Hyponatremia (< 130 mmol/L)
• Evidence of a significant medical disorder or laboratory finding that, in the opinion of the investigator, compromises the patient's safety during study participation, including any of the following:

• Uncontrolled infection or infection requiring a concurrent parenteral antibiotic
• Uncontrolled diabetes
• Congestive heart failure
• Myocardial infarction within the past 6 months
• Chronic renal disease
• Coagulopathy (excluding prophylactic anticoagulation)
• Known human immunodeficiency virus (HIV) positivity, hepatitis B surface antigen-positivity, or hepatitis C positivity with abnormal liver function tests

PRIOR CONCURRENT THERAPY:

• More than one prior chemotherapy regimen for SCLC
• Less than 24 hours from any prior radiotherapy or the likelihood of toxicity from prior radiotherapy
• Radiotherapy to > 25% of the bone marrow within the past 4 weeks
• Less than four weeks since major surgery

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Proacta, Incorporated

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Arizona Clinical Research Center, Incorporated

Tucson, Arizona, United States

Tower Cancer Research Foundation

Beverly Hills, California, United States

California Cancer Care, Incorporated - Greenbrae

Greenbrae, California, United States

Pacific Shores Medical Group - Long Beach

Long Beach, California, United States

Stanford Cancer Center

Stanford, California, United States

Front Range Cancer Specialists

Fort Collins, Colorado, United States

University of Florida Health Science Center - Jacksonville

Jacksonville, Florida, United States

Joliet Oncology-Hematology Associates, Limited - West

Joliet, Illinois, United States

Welborn Clinic

Evansville, Indiana, United States

James Graham Brown Cancer Center at University of Louisville

Louisville, Kentucky, United States

Kentuckiana Cancer Institute, PLLC

Louisville, Kentucky, United States

Purchase Cancer Group - Paducah

Paducah, Kentucky, United States

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States

Cancer and Blood Specialists of Nevada - Henderson

Henderson, Nevada, United States

Gabrail Cancer Center - Canton Office

Canton, Ohio, United States

Charles M. Barrett Cancer Center at University Hospital

Cincinnati, Ohio, United States

Good Samaritan Hospital Cancer Treatment Center

Cincinnati, Ohio, United States

Peninsula Cancer Institute - Newport News Office

Newport News, Virginia, United States

Countries

United States

Other Identifiers

PROACTA-PR-104-2001

Identifier Type: -

Identifier Source: secondary_id

PR104-2001

Identifier Type: -

Identifier Source: org_study_id